Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Beloranib

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Zafgen · Phase 2 · Completed · Enrollment 160

NCT01666691

ArmPopulationDoseWeeksEstimandWeight change
PlaceboObesity or overweightn/r12n/rn/r
0.3 mg BeloranibObesity or overweight0.3 mg12n/rn/r
0.6 mg BeloranibObesity or overweight0.6 mg12n/rn/r
1.2 mg BeloranibObesity or overweight1.2 mg12n/rn/r
2.4 mg BeloranibObesity or overweight2.4 mg12n/rn/r
3.2 mg BeloranibObesity or overweight3.2 mg12n/rn/r